Testicular Cancer Hits Chemours (CC) Shares Hard
Author By Sophia VidaPosted on Chemours fell 22% lower on Wednesday and Dupont 1.8% after Dupont was found liable for a man’s testicular cancer in a test case involving 3,500 lawsuits. According to two sources familiar with the matter, the jury awarded the man $5.1 million.
Though Dupont was found liable, its spinoff Chemours will bear the cost but said it will appeal the verdict.
Chemours retains defenses to claims that DuPont is entitled to indemnification from the judgment, according to Reuters.
Disclaimer: We have no position in Chemours Co (NYSE: CC) or E. I. du Pont de Nemours and Company (NYSE: DD) and have not been compensated for this article.
 Shares Hard){kind=link}